Aduro Biotech (NASDAQ: ADRO ): Q2 GAAP EPS of -$0.23 beats by $0.04 . More news on: Aduro BioTech, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BERKELEY, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of c...

AbbVie (NYSE: ABBV ) has acquired  Kirkland, WA-based Mavupharma , a privately held biopharma outfit developing cancer treatments based on the STING (STimulator on INterferon Genes) signaling pathway that plays a key role in the generation of an immune response to tumors. Financial te...